Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The American Society of Hematology (ASH) Annual Meeting and Exposition is the last big clinical conference of the year. As we head into 2024, which areas are set to attract investment with their latest datasets, and which are in danger of falling flat? ASH will see the latest data reveals on CAR-T products, multiple myeloma, leukaemia and…
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking. Following a difficult end to 2018, the biopharma industry recovered…
The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Evaluate Vantage Half-Year Review 2019 summaries the most significant trends across…
Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 1.7% CAGR between…
$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for…
2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC. 2018 started with the promise of a first-line lung…